Turn a stalled hold letter into a cleared submission and market launch, with a reviewer-ready response built by senior MedTech cybersecurity experts.
The short answer
Start the day the letter is issued: for 510(k), De Novo, and PMA major deficiencies you have 180 calendar days, or the submission is considered withdrawn. We deliver a gap analysis within 48 hours, map each deficiency to the missing evidence, build or fix that evidence (threat model, SBOM, testing, labeling) and draft a response the reviewer can check line by line. Clearance is always the FDA's decision.
275+ Devices Supported.
Trusted by leading MedTech companies
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
When a cybersecurity deficiency letter lands, the clock is running and the response needs to address every reviewer item precisely. The full engagement walks the letter, closes each item, and ships a single coherent response.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Every fda deficiency response engagement ships with the artifacts FDA reviewers expect to see - traceable, complete, and aligned with current guidance.
Every fda deficiency response engagement produces evidence aligned to the regulatory and consensus standards FDA reviewers and notified bodies expect to see - traceable, complete, and ready to drop into your ISO 13485 quality system.
Defines the SPDF, Section 524B submission package, threat modeling, SBOM, security architecture views, and cybersecurity testing every cyber device submission must include.
Statutory requirement that every cyber device 510(k), De Novo, PMA, and IDE submission include a complete cybersecurity package or face Refuse to Accept (RTA).
FDA's mandatory interactive submission template with structured upload slots for each cybersecurity artifact.
The consensus standard for medical device security risk management - asset, threat, vulnerability, likelihood, severity, and residual risk acceptability.
Foundational risk management standard. Cybersecurity risk is tied directly to patient-safety risk in the 14971 file.
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about - and what this engagement is built to cover.
AI-specific deficiency patterns surfaced after the 2023 PCCP guidance and the Jan 2025 AI/ML draft: missing crypto-agility narrative, missing input-validation evidence, missing PCCP cybersecurity boundary, and missing model-update threat analysis.
Reviewers increasingly call out missing or vague MPH architecture views, especially for cloud-connected devices. The 2026 final guidance makes MPH expectations explicit, and the deficiency rate on this single artifact rose materially.
Full-service: we own 100% of SPDF, SBOMs, threat modeling, pen testing, and eSTAR documentation.
View Full-Service FDA Premarket CybersecurityFull FDA premarket cybersecurity package for Software as a Medical Device - cloud, mobile, and web SaMD.
View SaMD CybersecurityCybersecurity content for Predetermined Change Control Plans, for AI/ML and non-AI devices.
View PCCP Cybersecurity ServicesCurated reading for teams working on fda deficiency response - grouped by format so you can jump to what you need.
Long-form reference reading - architecture, frameworks, and end-to-end how-tos.
Shorter posts on the specific gotchas, deficiencies, and reviewer expectations we see most.
Pressure-test the work yourself before you scope an engagement. No signup, results are yours to keep.
Turn a stalled hold letter into a cleared submission and market launch, with a reviewer-ready response built by senior MedTech cybersecurity experts.
FDA gives you up to 180 days to respond to a hold. Enter the date on your deficiency letter, AI request, or RTA notice to see your remaining response window.
Your remaining window will appear here once you pick a date.
Internal scrambling. Engineers pulled off the roadmap to reread the deficiency letter and Section 524B requirements.
Blue Goat We deliver the gap analysis within 48 hours and begin remediation so you're already responding within the first week.
Threat-model rewrites, hunting for SBOM data, scheduling pen tests. Launch slips, sales pipeline starts to hear about it.
Blue Goat By this point, our remediation package is complete and your revised submission is ready to file - before the review clock expires.
Approaching the 180-day FDA response window. A half-baked response risks another deficiency round and another 90+ days.
Blue Goat We engage directly with FDA guidance to ensure the response addresses the specific reviewer's expectations, not just the literal deficiency text.
Missed launch quarter. Investor questions. Competitors ship. Every additional FDA round can mean a full quarter of lost revenue.
Blue Goat This phase exists because teams didn't respond early enough. If you're here, we escalate - but the faster you engage, the more options you have.
Whether it is a deficiency letter, additional information request, or a full hold, we have seen it all and know exactly how to address it.
We dissect your FDA hold letter line by line, identifying exactly what the reviewer is asking for and what evidence is needed.
When the FDA asks for more info, we craft precise, complete responses that address every question without over-sharing.
If your threat model was flagged, we rebuild or strengthen it to meet FDA expectations, aligned with ANSI/AAMI SW96:2023 (which supersedes TIR57's normative role) and IEC 81001-5-1.
We perform or redo penetration testing to fill gaps the FDA identified, providing clean evidence of vulnerability management.
Missing SBOM, incomplete SPDF, or weak risk assessments? We identify what is missing and build it out for you.
We compile and format your entire deficiency response package, ready for eSTAR upload and FDA reviewer consumption.
A clear, four-step path. No mystery, no bloat. Senior-led from intake through submission.
Share your FDA deficiency letter, AI request, or RTA notice. Senior expert reviews within 1 business day.
We map every FDA finding to the evidence required and deliver a draft response strategy within 3 business days.
Threat model, SBOM/VEX, pen test, traceability, built by senior MedTech cybersecurity engineers, not handed to juniors.
A complete, reviewer-ready response formatted for eSTAR and built to clear on the first round.
Two responses to the same deficiency letter. Same device class. Different outcome.
What FDA reviewers see, and reject.
What FDA reviewers see, and accept.
One fixed fee. Every artifact your FDA reviewer expects, assembled and traceable.
Free 30-min call - senior expert, not a sales rep. NDA available on request.
Anonymized snapshots from recent FDA cybersecurity deficiency engagements.
Inherited a stalled 510(k) with threat model gaps, missing SBOM, and inadequate pen test coverage. Rebuilt the SPDF package and passed FDA cyber review on the first response.
RTA citing inadequate Section 524B documentation. Delivered a reviewer-ready response with updated security architecture views, SBOM + VEX, and traceability matrix.
High-stakes PMA with a complex Additional Information request. Coordinated retesting, threat model updates, and risk control evidence into a single complete response.
Client identities anonymized to protect submission confidentiality.
Every engagement is led by a senior expert on my team. They scope your work, direct our specialists, review every deliverable that goes to the FDA, and stay with you until your submission is cleared. Junior engineers contribute under that senior's direction; nothing reaches the FDA without senior review. No surprises.
